Press Release NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 6
Press Release NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results Aug 5
Press Release NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) Jul 24